<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62159">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02021136</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00613-42</org_study_id>
    <secondary_id>2013-A00613-42</secondary_id>
    <nct_id>NCT02021136</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Rebel Reliever Brace in Internal Femoral and Tibial Knee Osteoarthritis</brief_title>
  <acronym>ROTOR</acronym>
  <official_title>Efficacy and Safety of Rebel Reliever Brace in Internal Femoral and Tibial Knee Osteoarthritis. Phase 3, Multicenters, Randomised and Controlled Study With 2 Parallel Groups.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thuasne</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thuasne</source>
  <oversight_info>
    <authority>France: French Data Protection Authority</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate efficacy and safety of knee brace in the knee
      osteoarthritis treatment for pain after 6 weeks + antalgic usual treatment, physical
      exercices and avices compared to no knee brace + antalgic usual treatment, physical
      exercices and avices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main criteria is the evaluation of global knee pain during the last 24 hours at D 49
      after the inclusion.

      The response to the treatment will be evaluated during the inclusion visit (V1/D0) and after
      6 weeks of treatment, during the following visit (V3/D49).

      The level of the global pain of the patient during the last 24 hours will be collected by
      the rheumatologist with a VAS (0 mm = no pain ; 100mm = maximun pain) at each visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evolution of global knee pain over 24 last hours (VAS) at D49 compared to the inclusion</measure>
    <time_frame>After 6 weeks of brace wearing</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of global pain</measure>
    <time_frame>at Day 21</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation with Visual Analysis Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pourcentage of patients with at least one adverse event or serious adverse event in each groups.</measure>
    <time_frame>during the 6 weeks of brace wearing</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Rebel reliever</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient with rebel reliever + usual antalgic + physical exercices and advices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No brace</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with no rebel believer wearing + usual antalgic + physical exercices and advices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rebel reliever</intervention_name>
    <description>The patient must have the rebel reliever</description>
    <arm_group_label>Rebel reliever</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No brace</intervention_name>
    <description>The patient must not have the rebel reliever and no brace</description>
    <arm_group_label>No brace</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over 18 years

          -  BMI &lt; or egal to 35kg/m2

          -  symptomatic gonarthrosedefined by a recurrent pain to the walk on 30 days during the
             last 2 monthes before the inclusion

          -  diagnosis of internal femoro-tibial knee osteoarthrosis

          -  patient with global pain intensity during the last 24hours &gt; or egal 40 mm (EVA) at
             the day of selection

        Exclusion Criteria:

          -  femoro-patellaire symptomatic arthrosis

          -  septic arthritis

          -  metabolic arthropathies

          -  chronical rheumatismal diseases

          -  other knee diseases

          -  symptomatic coxarthrosis

          -  controlateral gonathrosis with corticoids injections
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe THOUMIE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coordinator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Euraxi Pharma</name>
      <address>
        <city>Joue-les-tours</city>
        <state>Bp 80325</state>
        <zip>37303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaumousse Arnaud</last_name>
      <phone>02 47 74 30 80</phone>
      <phone_ext>+33</phone_ext>
      <email>a.vaumousse@euraxipharma.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>October 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
